跳到正文
原文
Nature 健康护理主题·· 29 天前AI 评分52

自发性脑出血前后血压控制:中风服务审计与改进策略

Blood pressure control before and after spontaneous intracerebral haemorrhage: a stroke service audit and strategies for improvement

AI 导读

一项回顾性审计分析89例自发性脑出血患者,发现发病前一年仅56.2%患者达到NICE血压控制目标(<140/90 mmHg),尽管79.8%患者有高血压诊断。发病后血压控制有所改善,但仅38.4%达到ESO二级预防目标(<130/80 mmHg),且出院后首次社区血压监测中位延迟62天。研究建议结合远程监测与药师或护士主导的剂量调整,建立结构化的出院后血压管理路径。

正文

Abstract

In a retrospective audit of 89 adults with spontaneous intracerebral haemorrhage (ICH) at a tertiary neuroscience centre, fewer than 60% met the National Institute for Health and Care Excellence (NICE) blood pressure (BP) target in the year before their haemorrhage, despite most carrying a known diagnosis of hypertension. Blood pressure control and antihypertensive prescribing improved after ICH, yet most survivors remained above the European Stroke Organisation (ESO) secondary-prevention target, and the first documented community BP check occurred a median of 62 days after discharge. These findings expose primary- and secondary-prevention gaps spanning the whole care pathway and lend support to a structured, protocolised uptitration pathway after discharge, combining remote BP monitoring with pharmacist- or nurse-led dose escalation.

Hypertension is the leading modifiable risk factor for spontaneous ICH, accounting for the majority of its population-attributable risk, and ICH remains among the most devastating stroke subtypes [1]. Sustained BP lowering reduces the risk of haemorrhagic stroke [2], and inadequate post-ICH control is independently associated with recurrence [3], yet real-world UK data describing BP control across the full ICH care pathway remain limited [4]. NICE recommends a primary-care treatment target of <140/90 mmHg [5], while following ICH the ESO recommends intensification to <130/80 mmHg for secondary prevention [6]. The 2024 European Society of Cardiology guidance now advocates an on-treatment systolic target of 120–129 mmHg for most patients in whom it is tolerated [7], widening the divergence between UK and European recommendations.

This retrospective single-centre audit was conducted at the National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust (registration 32-202627-CA). We included adults with CT-confirmed spontaneous ICH admitted between 1 January 2023 and 1 January 2025 who were alive at data extraction and had at least one primary-care BP reading in the preceding 12 months accessible through the London Care Record (LCR). Traumatic, subarachnoid, and haemorrhagic-transformation cases were excluded. Of 4037 suspected strokes, 273 patients had ICH however only 89 met the eligibility criteria with the commonest reasons for exclusion being death before extraction (n = 60) and absent pre-admission GP BP data (n = 124). Community (pre-ICH and post-discharge) and inpatient readings were assessed against NICE (<140/90 mmHg) and ESO (<130/80 mmHg) thresholds, requiring both mean systolic (SBP) and diastolic BP to fall below target. Paired comparisons used the Wilcoxon signed-rank or paired t-test and McNemar’s test, in Python 3.10.9.

The 89 included patients had a median age of 67.9 years (IQR 59.6–79.6) and 53 (59.6%) were male. ICH was deep in 58 (65.2%), lobar in 27 (30.3%), and isolated intraventricular in 4 (4.5%), with a median length of stay of 7.0 days. Known hypertension was present in 71 of 89 (79.8%). In the 12 months before ICH, median SBP was 139.0 mmHg (IQR 130.0–147.5), yet only 50 of 89 (56.2%, 95% CI 45.8–66.0) met the NICE target (Table 1). GP recording was sparse, 23 patients had a single pre-ICH reading and the median interval from last recorded GP BP to admission was 61 days, and no consistent rise in SBP was apparent in the weeks immediately preceding the event on smoothed trajectory analysis, although the density of readings in the final 30 days was low.

Table 1 Blood pressure across pre-ICH, admission, and post-ICH periods.

Full size table

Median admission SBP was 162.5 mmHg (IQR 146.6–189.9) and intravenous treatment was required in 52 of 89 patients (58.4%), consistent with the acute hypertensive response that characteristically accompanies ICH; only 16 of 89 (18.0%) met the NICE target at admission. Prescribing intensified markedly during admission: the proportion on any antihypertensive agent rose from 69.7% to 86.5% and the median number of drug classes from one to two (p < 0.001), with the largest increases in calcium-channel blockers, alpha-blockers, and ACE inhibitors. Overall, 53 patients (59.6%) had their regimen escalated, and 18 of 27 previously untreated patients (66.7%) were started on at least one agent before discharge. By discharge, median SBP had fallen to 129.7 mmHg.

Post-discharge community readings were available for 86 of 89 patients (96.6%). Median post-ICH SBP was 127.0 mmHg (IQR 121.5–135.2), a reduction of 12.0 mmHg from the pre-ICH period (p < 0.001). NICE control rose to 74 of 86 (86.0%), but only 33 of 86 (38.4%) met the ESO target, leaving 61.6% above the secondary-prevention threshold [3]; at the individual level, 64 patients had a lower mean SBP after ICH, although 19 had a higher value. The first documented community BP check occurred a median of 62 days after discharge (IQR 22–170). Among the 45 patients with three or more pre-ICH readings, visit-to-visit variability was noted (median average real variability of SBP 15.7 mmHg; coefficient of variation 10.1%), consistent with variability representing a clinically relevant dimension of risk beyond mean BP [8].

Most patients in this cohort sustained an ICH while above the NICE threshold despite a recognised diagnosis of hypertension, underlining that prevention of a first haemorrhage depends not only on detecting hypertension but on treating it to sufficiently stringent targets. This gap is multifactorial, spanning clinical factors such as uncertainty about intensification, patient factors including non-adherence and loss to follow-up, and system factors such as time-pressured consultations and fragmented primary–secondary care communication [9]. Given that hypertension accounts for the majority of the population-attributable risk for ICH [1], our findings add to the case for considering more intensive primary-prevention targets, aligned more closely with contemporary European recommendations, with a deliberate shift away from the previous stepped approach, weighed against the risks of overtreatment and treatment burden in older and frailer patients.

Inpatient management appeared proactive, but the prolonged interval to first community follow-up marks discharge as the critical weak point in the secondary-prevention pathway. Intensive BP lowering is effective in this setting and has recently been reinforced by the TRIDENT trial [10]. Structured, protocolised uptitration offers a tested route to closing this gap. In heart failure, digitally enabled titration services have compressed treatment optimisation from many months to a matter of weeks while reducing outpatient attendance, an approach now recognised as a national case study within the Cardiovascular Disease Modern Service Framework [11]. The same architecture with a defined target, protocolised dose escalation, remote monitoring, and pharmacist- or nurse-led review between clinic visits maps readily onto post-ICH BP management, where there is a clear target (<130/80 mmHg) and the antihypertensives are familiar. Such a platform with structured blood pressure monitoring would directly address the follow-up delay by capturing readings outside the clinic and supporting timely titration [12]. This approach is endorsed by NHS England and home blood pressure monitoring is under evaluation in the ongoing EPIC-ICS feasibility trial, with 24-hour ambulatory monitoring offering an alternative where home monitoring is impractical.

Several limitations should be acknowledged. This was a single-centre retrospective audit restricted to patients with pre-admission BP data accessible through the LCR, introducing potential selection and survival bias, and opportunistic GP recording may underestimate the true burden of uncontrolled hypertension; discharge prescribing also reflects intent rather than long-term adherence. Nonetheless, examined across a complete care pathway, BP was inadequately controlled before ICH in over 40% of patients, and most survivors remained above secondary-prevention targets despite improved control. These represent substantial and largely addressable prevention gaps, and the post-discharge gap in particular is one that a structured, scalable uptitration pathway could begin to close.

Data availability

The data generated and analysed during this audit are not publicly available owing to information-governance restrictions on patient-level NHS records but are available from the corresponding author on reasonable request.

References

  1. Wolsink A, Citeur MP, van Asch CJ, Boogaarts H, Dammers R, Hannink G, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage, according to age, sex, and country income level: a systematic review and meta-analysis. Lancet Reg Health Eur. 2025;49:101180.

    Article  PubMed  Google Scholar 

  2. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–41.

    Article  Google Scholar 

  3. Biffi A, Anderson CD, Battey TWK, Ayres AM, Greenberg SM, Vinswanathan A, et al. Association between blood pressure control and risk of recurrent intracerebral hemorrhage. JAMA. 2015;314:904–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mullen MT, Anderson CS. Review of long-term blood pressure control after intracerebral hemorrhage: challenges and opportunities. Stroke. 2022;53:2142–51.

    Article  PubMed  Google Scholar 

  5. NICE, NG136 Hypertension in adults: diagnosis and management. 2019. https://www.nice.org.uk/guidance/ng136

  6. Sandset EC, Anderson CS, Bath PM, Christensen H, Fischer U, Gasecki D, et al. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. Eur Stroke J. 2021;6:II.

    Article  PubMed  PubMed Central  Google Scholar 

  7. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912–4018.

    Article  PubMed  Google Scholar 

  8. Rothwell PM, Howard SC, Dolan E, Dobson JE, Dahlof B, Sever PS, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895–905.

    Article  PubMed  Google Scholar 

  9. Lu Y, Arowojolu O, Qiu X, Liu Y, Curry LA, Krumholz HM. Barriers to optimal clinician guideline adherence in management of markedly elevated blood pressure: a qualitative study. JAMA Netw Open. 2024;7:e2426135.

    Article  PubMed  PubMed Central  Google Scholar 

  10. TRIDENT Investigators, Anderson CS, Chow CK, de Silva HA, Senanayake B, Wahab K, et al. Three low-dose antihypertensive agents in a single pill after intracerebral hemorrhage. N Engl J Med. 2026;394:1571–82.

    Article  Google Scholar 

  11. Department of Health and Social Care and NHS England, Cardiovascular disease (CVD) modern service framework: a cardiovascular-kidney-metabolic approach — the strategic vision and delivery model. 2026: https://www.gov.uk/government/publications/cardiovascular-disease-modern-service-framework.

  12. Tran KC, Mak M, Kuyper LM, Bittman J, Mangat B, Lindsay H, et al. Home blood pressure telemonitoring technology for patients with asymptomatic elevated blood pressure discharged from the emergency department: pilot study. JMIR Form Res. 2024;8:e49592.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

CZ is supported by an NIHR Academic Clinical Fellowship (ACF-2024-18-002). DW, MG: none.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, University College London NHS Foundation Trust, London, UK

    Claudia Zeicu & Marc George

  2. Stroke Research Centre, Department of Translational Neuroscience and Stroke, Queen Square Institute of Neurology, University College London, and National Hospital for Neurology and Neurosurgery, London, UK

    David J. Werring

Authors

  1. Claudia Zeicu
  2. David J. Werring
  3. Marc George

Contributions

CZ collected and analysed the data and drafted the manuscript. DJW contributed to study design. MG supervised the study and clinical pharmacology interpretation. All authors critically revised the manuscript and approved the final version.

Corresponding author

Correspondence to Marc George.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethical approval

This work was conducted as a registered clinical audit/service evaluation at the National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust (registration number 32-202627-CA). As a service evaluation using routinely collected clinical data, it did not require Health Research Authority research ethics committee approval.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zeicu, C., Werring, D.J. & George, M. Blood pressure control before and after spontaneous intracerebral haemorrhage: a stroke service audit and strategies for improvement. J Hum Hypertens (2026). https://doi.org/10.1038/s41371-026-01243-5

Download citation

  • Received: 25 July 2026

  • Revised: 07 September 2026

  • Accepted: 29 September 2026

  • Published: 23 October 2026

  • Version of record: 23 October 2026

  • DOI: https://doi.org/10.1038/s41371-026-01243-5

来源:Nature 健康护理主题 · nature.com